“Ichilov”: Efficacy for factsol in the treatment of recurrent prostate cancer without metastases

A study conducted at the Ichilov-Tel Aviv Medical Center showed promising results in the treatment of pectasol in prostate cancer patients in the case of recurrence of non-metastatic disease. Factol is a natural substance that inhibits the protein galactin 3, which is involved in the tumor process and in the recurrence of prostate cancer. “Prostate cancer is the most common tumor in men in the Western world, with a third of patients showing recurrence after initial treatment with surgery or radiation. When recurrence is manifested by an increase in the PSA marker without metastases – there is currently no proven treatment.” For the course of the disease without treatment in which the majority of patients (about 80%) show a worsening of the disease indices within six months, it has now been proven that the treatment with factsol led to a stabilization of the disease by 78% (only 22% showed disease progression).

The results of the study were recently published in the journal NUTRIENTS and it is soon planned to start a larger study – Phase 3.

Note: This article has been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
The STI Epidemic Is Out of Control thumbnail

The STI Epidemic Is Out of Control

Sexually transmitted infections (STIs) are epidemic in the U.S. This April, the CDC reported that cases of gonorrhea, chlamydia, and syphilis were at an all-time high for the sixth consecutive year. STIs affect everyone across the country and are most common in those under 25 years of age. Untreated STIs cost our society billions of…
Read More
New Hope Against Painful Skin Issues Caused by Radiation Therapy thumbnail

New Hope Against Painful Skin Issues Caused by Radiation Therapy

Please enable cookies. Error 1005 Ray ID: 7d87bde2ada631d5 • 2023-06-17 02:07:55 UTC What happened? The owner of this website (www.webmd.com) has banned the autonomous system number (ASN) your IP address is in (47583) from accessing this website. Was this page helpful? Thank you for your feedback! Cloudflare Ray ID: 7d87bde2ada631d5 • Your IP: 89.117.245.16 •
Read More
'It's Total Charlatanism': What We Heard This Week thumbnail

‘It’s Total Charlatanism’: What We Heard This Week

Opinion > What We Heard This Week — Quotable quotes heard by MedPage Today's reporters by MedPage Today Staff July 2, 2023 "It's total charlatanism." -- Thomas Albini, MD, of the University of Miami in Florida, discussing eye injuries from unproven stem cell treatments claiming to treat eye and neurological conditions. "To see something like
Read More
Choosing a Treatment Regimen for Your Endometrial Cancer Patients thumbnail

Choosing a Treatment Regimen for Your Endometrial Cancer Patients

The conversation at the Society of Gynecologic Oncology (SGO) annual meeting was dominated by the two randomized phase III trials that showed improved progression-free survival (PFS) for patients with advanced or recurrent endometrial cancer treated with immunotherapy. But now the conversation turns to the practice. How do you select a frontline treatment for your patients?
Read More
Index Of News
Total
0
Share